Summary of demographic information and outcomes of trials included in the analysis
| Study . | Drug . | N . | CHADS2, mean ± SD . | Ischemic stroke/SE, %/y . | Major bleeding, %/y . | Death from ischemic stroke/SE, %/y . | Death from major bleeding, %/y . | Reference . |
|---|---|---|---|---|---|---|---|---|
| ROCKET AF | Rivaroxaban | 7131 | 3.48 ± 0.94 | 1.38 | 3.60 | 0.24 | 0.24 | 3 |
| Dose-adjusted warfarin | 7133 | 3.48 ± 0.95 | 1.61 | 3.45 | 0.32 | 0.48 | ||
| J-ROCKET AF | Rivaroxaban | 639 | 3.27 ± 0.85 | 0.91 | 3.00 | NA | 0.11 | 19 |
| Dose-adjusted warfarin | 639 | 3.27 ± 0.87 | 2.14 | 3.59 | NA | 0.35 | ||
| ARISTOTLE | Apixaban | 9120 | 2.10 ± 1.10 | 0.80 | 2.13 | NA | 0.06 | 4 |
| Dose-adjusted warfarin | 9081 | 2.10 ± 1.10 | 0.86 | 3.09 | NA | 0.24 | ||
| AVERROES | Apixaban | 2807 | 2.00 ± 1.10 | 1.20 | 1.41 | NA | NA | 20 |
| ENGAGE AF-TIMI 48 | Edoxaban | 7035 | 2.80 ± 1.00 | 0.93 | 2.75 | 0.23 | 0.18 | 5 |
| Edoxaban | 7034 | 2.80 ± 1.00 | 1.49 | 1.61 | 0.28 | 0.12 | ||
| Dose-adjusted warfarin | 7036 | 2.80 ± 1.00 | 1.01 | 3.43 | 0.24 | 0.33 | ||
| Overall (FXa inhibitors) | – | 33 766 | 2.70 ± 1.02 | 1.13 | 2.42 | 0.31 | 0.14 | – |
| Overall (warfarin) | – | 23 889 | 2.75 ± 1.02 | 1.16 | 3.31 | 0.28 | 0.34 | – |
| Overall (all arms) | – | 57 655 | 2.72 ± 1.02 | 1.14 | 2.79 | 0.30 | 0.23 | – |
| Study . | Drug . | N . | CHADS2, mean ± SD . | Ischemic stroke/SE, %/y . | Major bleeding, %/y . | Death from ischemic stroke/SE, %/y . | Death from major bleeding, %/y . | Reference . |
|---|---|---|---|---|---|---|---|---|
| ROCKET AF | Rivaroxaban | 7131 | 3.48 ± 0.94 | 1.38 | 3.60 | 0.24 | 0.24 | 3 |
| Dose-adjusted warfarin | 7133 | 3.48 ± 0.95 | 1.61 | 3.45 | 0.32 | 0.48 | ||
| J-ROCKET AF | Rivaroxaban | 639 | 3.27 ± 0.85 | 0.91 | 3.00 | NA | 0.11 | 19 |
| Dose-adjusted warfarin | 639 | 3.27 ± 0.87 | 2.14 | 3.59 | NA | 0.35 | ||
| ARISTOTLE | Apixaban | 9120 | 2.10 ± 1.10 | 0.80 | 2.13 | NA | 0.06 | 4 |
| Dose-adjusted warfarin | 9081 | 2.10 ± 1.10 | 0.86 | 3.09 | NA | 0.24 | ||
| AVERROES | Apixaban | 2807 | 2.00 ± 1.10 | 1.20 | 1.41 | NA | NA | 20 |
| ENGAGE AF-TIMI 48 | Edoxaban | 7035 | 2.80 ± 1.00 | 0.93 | 2.75 | 0.23 | 0.18 | 5 |
| Edoxaban | 7034 | 2.80 ± 1.00 | 1.49 | 1.61 | 0.28 | 0.12 | ||
| Dose-adjusted warfarin | 7036 | 2.80 ± 1.00 | 1.01 | 3.43 | 0.24 | 0.33 | ||
| Overall (FXa inhibitors) | – | 33 766 | 2.70 ± 1.02 | 1.13 | 2.42 | 0.31 | 0.14 | – |
| Overall (warfarin) | – | 23 889 | 2.75 ± 1.02 | 1.16 | 3.31 | 0.28 | 0.34 | – |
| Overall (all arms) | – | 57 655 | 2.72 ± 1.02 | 1.14 | 2.79 | 0.30 | 0.23 | – |
ARISTOTLE, Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; AVERROES, Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment; ENGAGE AF-TIMI 48, Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48; J-ROCKET AF, Japanese Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; N, number of patients; NA, not available; ROCKET AF, Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; SD, standard deviation.